Hyderabad-based Biological E has, however, proposed to manufacture about 30 crore doses of its indigenous vaccine exclusively for the Indian market by December.
Johnson and Johnson s COVID-19 vaccine to be manufactured in India by Biological E cannot be directly channelled to the domestic market and will have to be handed over entirely to the US pharma giant as agreed by the firms but the government is looking at the possibility of securing a part of this production, sources said. Hyderabad-based Biological E has, however, proposed to manufacture about 30 crore doses of its indigenous vaccine exclusively for the Indian market by December and has sought funding support from the government. Its vaccine candidate is currently in phase 1/2 clinical trial phase. According to the sources, there are limited prospects of J&J exporting its vaccine from the US to other countries in the near future and the entire production at the BE facilities in India, beginning July/August, will be handed over to the pharma giant under a contract between the companies.
Biological E has, however, proposed to manufacture about 30 crore doses of its indigenous vaccine exclusively for India by December and has sought "funding support".
India News: NEW DELHI: Johnson and Johnson's Covid-19 vaccine to be manufactured in India by Biological E cannot be directly channelled to the domestic market and.
Centre Looking Into Securing Part Of J&J Vaccine Shots For India: Report Centre Looking Into Securing Part Of J&J Vaccine Shots For India: Report Hyderabad-based Biological E has proposed to manufacture about 30 crore doses of its indigenous vaccine exclusively for the Indian market by December.
Updated: May 26, 2021 11:37 pm IST
There are limited prospects of J&J exporting its vaccine from US to other countries, sources said (File)
New Delhi:
Johnson and Johnson s (J&J) COVID-19 vaccine, to be manufactured in India by Biological E, cannot be directly channelled to the domestic market and will have to be handed over entirely to the US pharma giant as agreed by the firms but the government is looking at the possibility of securing a part of this production, sources said.